Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

[News]

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

More... (http://www.news-medical.net/news/20141107/Olaparib-shows-promise-for-advanced-cancers-associated-with-BRCA1-and-BRCA2-mutations.aspx)